Expression of IL-10 in human normal and cancerous ovarian tissues and cells.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  European Cytokine Network

• Publication date

  2010-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1684/ecn.2010.0188PMID 20430716
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Monitoring of IL-10 in the serum of patients with advanced ovarian cancer: results from a prospective pilot-study.

  2009cited by this paper
• Evaluation of immune inhibitory cytokine profiles in epithelial ovarian carcinoma

  2009cited by this paper
• Regulation of ovarian carcinoma SKOV-3 cell proliferation and secretion of MMPs by autocrine IL-6.

  2007cited by this paper
• The Expression of Interleukin-10 in Patients with Primary Ovarian Epithelial Carcinoma and in Ovarian Carcinoma Cell Lines

  2007cited by this paper
• Expression of IL-10 in patients with ovarian carcinoma.

  2006cited by this paper
• Interleukin‐10 in viral diseases and cancer: exiting the labyrinth?

  2004cited by this paper
• Increased Interleukin-10 mRNA Stability in Melanoma Cells Is Associated with Decreased Levels of A + U-Rich Element Binding Factor AUF1

  2003cited by this paper
• Tumour necrosis factor α: a potential target for the therapy of solid tumours

  2003cited by this paper
• Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer.

  2003cited by this paper
• Tumour necrosis factor alpha: a potential target for the therapy of solid tumours.

  2003cited by this paper
• Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.

  2002cited by this paper
• Cytokines and Immune Response in the Tumor Microenvironment

  2001cited by this paper
• Interleukin-10 in serous ovarian carcinoma cell lines

  2001cited by this paper
• Interleukin-10 and the interleukin-10 receptor.

  2001cited by this paper
• Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer.

  2001influential reference
• Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10.

  2000cited by this paper
• Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion.

  1999cited by this paper
• Interleukin-10: a cytokine used by tumors to escape immunosurveillance

  1999cited by this paper
• The role of cytokines in both the normal and malignant ovary.

  1999cited by this paper
• Tumor necrosis factor-alpha and interleukin-6 are differently expressed by fresh human cancerous ovarian tissue and primary cell lines.

  1998cited by this paper
• Interleukin‐10 is a growth factor for human melanoma cells and down‐regulates HLA class‐I, HLA class‐II and ICAM‐1 molecules

  1997cited by this paper
• Distinct patterns of expression of interleukin-1 alpha and beta by normal and cancerous human ovarian tissues.

  1997cited by this paper
• Tumor-host interaction: analysis of cytokines, growth factors, and tumor-infiltrating lymphocytes in ovarian carcinomas.

  1996cited by this paper
• IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells.

  1995cited by this paper
• IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response.

  1995cited by this paper
• Cancer of the ovary.

  1994cited by this paper
• Cancer of the ovary.

  1993cited by this paper
• Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance.

  1993cited by this paper
• IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression.

  1993cited by this paper
• Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies.

  1992cited by this paper
• Presence of interleukin 10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers.

  1992cited by this paper
• IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells.

  1991cited by this paper
• Epithelial ovarian cancer: a cytokine propelled disease?

  1991cited by this paper
• Macrophage deactivation by interleukin 10

  1991cited by this paper

• Optimising Chemotherapy for Advanced High-Grade Serous Ovarian Cancer via Delay-Differential Equations

  2025cites this paper
• Harnessing Antitumor Immunity in Ovarian Cancer.

  2024cites this paper
• The complex role of IL-10 in malignant ascites: a review

  2024cites this paper
• Biomarkers in Urolithiasis.

  2023cites this paper
• Co-treatment of Naringenin and Ketoprofen-RGD Suppresses Cell Proliferation via Calmodulin/PDE/cAMP/PKA Axis Pathway in Leukemia and Ovarian Cancer Cells

  2023cites this paper
• Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors.

  2022cites this paper
• [Correlation between adipokine and clinicopathological features and prognosis in upper tract urothelial carcinoma].

  2022cites this paper
• IL-10 Signaling in the Tumor Microenvironment of Ovarian Cancer.

  2021cites this paper
• Shock wave lithotripsy, for the treatment of kidney stones, results in changes to routine blood tests and novel biomarkers: a prospective clinical pilot-study

  2020cites this paper
• Cytokines in peritoneal fluid of ovarian neoplasms

  2020cites this paper
• Immunology and Immunotherapy of Ovarian Cancer

  2020cites this paper
• Immunotherapy in Ovarian Cancer: Are We There Yet?

  2019cites this paper
• Ascites IL-10 Promotes Ovarian Cancer Cell Migration

  2018cites this paper
• Interleukin-10 and prostaglandin E2 have complementary but distinct suppressive effects on Toll-like receptor-mediated dendritic cell activation in ovarian carcinoma

  2017cites this paper
• IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients

  2017cites this paper
• Atractylenolide I modulates ovarian cancer cell-mediated immunosuppression by blocking MD-2/TLR4 complex-mediated MyD88/NF-κB signaling in vitro

  2016cites this paper
• University of Southern Denmark The immune response is affected for at least three weeks after extensive surgery for ovarian cancer Brøchner,

  2016cites this paper
• Syddansk Universitet The immune response is affected for at least three weeks after extensive surgery for ovarian cancer Brøchner,

  2016cites this paper
• Cytokines and Prognostic Factors in Epithelial Ovarian Cancer

  2016cites this paper
• Targeting Programmed Cell Death 1 in Ovarian Cancer.

  2015cites this paper
• Distinct expression and localization of TNF system in ovarian carcinoma tissues: possible involvement of TNF-α in morphological changes of ovarian cancerous cells.

  2014cites this paper
• Expression of IL-18, IL-18 Binding Protein, and IL-18 Receptor by Normal and Cancerous Human Ovarian Tissues: Possible Implication of IL-18 in the Pathogenesis of Ovarian Carcinoma

  2014cites this paper
• Immunohistochemical staining of tumor necrosis factor-α and interleukin-10 in benign and malignant ovarian neoplasms

  2014cites this paper
• Interaction of Immune and Cancer Cells

  2014cites this paper
• Interleukin-10 Superfamily and Cancer

  2014cites this paper
• Serum IL-10 and IL-12 levels reflect the response to chemotherapy but are influenced by G-CSF therapy and sepsis in children with soft tissue sarcomas.

  2013cites this paper
• Oncogramme, an Adapted Method for Individualized Tumour Response Testing of Ovary Cancer Treatments

  2013cites this paper
• Thalidomide distinctly affected TNF-α, IL-6 and MMP secretion by an ovarian cancer cell line (SKOV-3) and primary ovarian cancer cells.

  2013cites this paper
• Deregulated systemic IL-10/IL-12 balance in advanced and poor prognosis paediatric soft tissue sarcomas

  2013cites this paper
• Loss of IL-10 Decreases Mouse Postpubertal Mammary Gland Development in the Absence of Inflammation

  2012cites this paper
• Overexpression and immunosuppressive functions of transforming growth factor 1, vascular endothelial growth factor and interleukin-10 in epithelial ovarian cancer

  2012cites this paper
• Peritoneal Immune System in Patients with Advance Epithelial Ovarian Cancer

  2011cites this paper
• Evaluation of IL-10 and TGF-β levels and myeloid and lymphoid dendritic cells in ovarian cancer patients.

  2011cites this paper